ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2025
From guidelines to global impact: updates to address disparities in hereditary angioedema care.
Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toward equitable and evidence-based care in Hereditary Angioedema: Time for inclusive global guidelines.The World Allergy Organization journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent subcutaneous and/or submucosal edema, most commonly caused by deficiency in C1-esterase inhibitor. There has been a paradigm shift in treatment goals—from merely managing acute attacks to improving or normalizing quality of life, thanks to the availability and accessibility of modern, HAE-specific medications. However, for a large majority of countries in the world, HAE-specific medications are still not available or accessible. The correspondence on ‘The International/Canadian Hereditary Angioedema Guideline’ tries to address global disparities in HAE care, highlight the key challenges in low- and middle-income countries and provide potentially viable and equitable solution to address disparities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.